mRNA Lipid Composition Analysis Service
In the rapidly evolving landscape of mRNA-based vaccine development, the success of a therapeutic candidate is as much about the delivery vehicle as it is about the genetic payload. Lipid nanoparticles (LNPs) have emerged as the gold standard for protecting fragile mRNA and ensuring its efficient intracellular delivery. However, the precise ratio and chemical integrity of the lipid components, typically comprising ionizable lipids, phospholipids, cholesterol, and polyethylene glycol (PEG) lipids, are critical quality attributes that directly dictate the stability, safety, and efficacy of the drug product.
At CD BioGlyco, we recognize that even minor deviations in lipid composition lead to particle aggregation, reduced encapsulation efficiency, or altered biodistribution. Our mRNA lipid composition analysis service provides a high-resolution window into the molecular architecture of your LNPs. By leveraging sophisticated analytical platforms, we help researchers and pharmaceutical developers ensure that their formulations meet stringent performance benchmarks.
As part of our mRNA structural characterization offerings, CD BioGlyco provides a comprehensive suite of analytical services tailored to the unique needs of the mRNA-based vaccine development pipeline. Our service scope includes:
Upon receiving your mRNA-LNP samples, our team performs a controlled disassembly of the nanoparticles using optimized organic solvent extraction methods. This step ensures that all lipid components are fully recovered and solubilized.
CD BioGlyco's experts select the most appropriate chromatographic columns and mobile phase gradients based on your specific lipid species. We optimize the separation parameters to ensure high resolution.
We utilize certified reference standards to establish multi-point calibration curves. System suitability tests are performed before each run to verify the accuracy, precision, and sensitivity of the instrument for the targeted analytes.
Samples are analyzed using UHPLC coupled with CAD or MS detection. Our advanced separation techniques minimize matrix interference, allowing for the clear identification of each component within complex LNP matrices.
Raw data are integrated using sophisticated software. We calculate the absolute concentration and molar percentage of each lipid, ensuring that the results are statistically significant and reproducible.
Clients receive a detailed analytical report including chromatograms, mass spectra, quantitative data, and a summary of findings. Our experts are available to discuss the implications of the data for your formulation strategy.
DoI: 10.1016/j.ejps.2025.107182
Journal: European Journal of Pharmaceutical Sciences
IF: 4.7
Published: 2025
Results: This study investigates how helper lipids (DOPE/DSPC), PEG-lipids (PEG-DMG/PEG-DMPE), and RNA cargo (siRNA/mRNA) affect LNP performance for pulmonary delivery. Based on the formulation (ionizable lipid MC3 + cholesterol), eight LNP variants were prepared and characterized. All LNPs showed ~100 nm diameter, low PDI (<0.2), and 72-79% encapsulation efficiency, with minimal impact from lipid substitutions. DOPE-containing LNPs formed inverted hexagonal phases, enhancing siRNA endosomal escape and gene silencing but reducing storage stability. mRNA LNPs showed no transfection differences across lipids, likely due to mRNA's larger size limiting endosomal escape. All LNPs penetrated mucus in Calu-3 air-liquid interface models, achieving GAPDH silencing. Lipid composition shaped protein corona formation in lung mucus, with DSPC-containing LNPs adsorbing more proteins. These findings highlight helper lipids and RNA cargo as key determinants of LNP efficacy, providing insights for optimizing pulmonary RNA delivery systems.
Fig.1 The impact of lipid compositions on siRNA and mRNA lipid nanoparticle performance. (Rademacker, et al., 2025)
Infectious Disease Vaccines
Our analysis ensures the consistency of mRNA vaccines for pathogens like influenza and emerging viruses, where precise lipid ratios are vital for triggering a potent and safe immune response.
Cancer Immunotherapy
We support the development of personalized mRNA cancer vaccines by characterizing LNPs designed for targeted delivery to dendritic cells or the tumor microenvironment to enhance therapeutic efficacy.
Gene Editing Delivery
For base-editing therapies, our services verify the integrity of LNPs carrying large mRNA payloads, ensuring they maintain structural stability during complex delivery routes to specific organs.
Rare Disease Protein Replacement
We provide critical QC for mRNA therapeutics aimed at treating genetic disorders, ensuring that long-term, repeated dosing is supported by a stable and well-characterized lipid delivery system.
Exceptional Sensitivity and Accuracy
Our UHPLC-CAD and LC-MS detect trace-level lipids and impurities that traditional methods miss, ensuring your formulation is fully characterized at the highest resolution.
Extensive Lipidomics Expertise
With years of experience in complex lipid analysis, our scientists understand the nuances of ionizable lipids and PEG-conjugates, providing deeper insights than standard analytical laboratories.
Tailored Analytical Solutions
Every project receives a customized method development plan optimized for your specific proprietary lipids and unique LNP formulation requirements.
Comprehensive Characterization Suite
Beyond composition, we offer integrated services like stability testing and impurity profiling, providing a one-stop shop for all your mRNA structural characterization and lipid analysis needs.
Their UHPLC-CAD method was far more sensitive than our internal UV assays, allowing us to detect critical degradation products early in our stability study.
— A.U., Senior Scientist
CD BioGlyco developed a custom LC-MS method that gave us the accuracy we needed. Their expertise in lipid chemistry is truly unmatched in the industry.
— W.R., Director of Analytical Chemistry
Their turnaround times are reliable, and the technical support they provide during the data interpretation phase added significant value to our mRNA therapeutic program.
— S.T., Principal Investigator
At CD BioGlyco, our mRNA lipid composition analysis service combines state-of-the-art detection technologies with deep biological expertise to ensure your LNPs are safe, stable, and effective. Please feel free to contact us to learn more about our services or to request a quote.
Reference
